What type of cancer is Umbralisib used to treat? Has it been launched abroad?

Umbralisib (trade name UKONIQ) is an oral small molecule inhibitor that mainly targets PI3Kδ and CK1ε kinases. It is a targeted therapy drug. It is mainly used to treat certain types of non-Hodgkin lymphoma, especially relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). In addition, Albliside is also used for chronic lymphocytic leukemia (CLL) and other B cell-related hematological malignancies.

In clinical trials, Albuliside has shown certain anti-tumor activity, especially in the treatment of patients with relapsed or refractory lymphoma. Its mechanism of action is to inhibit the proliferation and survival of tumor cells by blocking the PI3Kδ signaling pathway, thereby achieving the purpose of controlling the disease. Due to the convenience of its oral administration, Albliside provides patients with a more convenient treatment option compared to traditional chemotherapy.

In foreign markets, Oblise received accelerated approval from the U.S. FDA in 2021, allowing it to be used to treat patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma. However, with the disclosure of subsequent clinical data, especially the emergence of safety issues, the FDA withdrew its marketing approval for the drug in 2022, resulting in the suspension of sales in the US market. Europe and other regions have also suspended sales and approval processes for the drug.

To sum up, Erbliside is a targeted treatment drug for specific lymphoma. It was briefly approved for marketing abroad, but was withdrawn from the market due to safety issues. At present, Alblisid has not yet obtained sustained market access in most major countries. Patients should consult a professional doctor before use to understand the latest treatment options and drug policies.

Reference materials:https://www.drugs.com/